IDEXX reported strong Q4 2025 results with 12% organic revenue growth, driven by robust instrument placements and double-digit CAG diagnostics recurring revenue growth. Management initiated 2026 guidance for 7-9% organic revenue growth and 10-14% EPS growth, expecting continued macro headwinds but stable execution. Q4 2025 organic revenue growth of 12%, with CAG diagnostics recurring revenue up 10% organically.
IDEXX reported strong Q4 2025 results with 12% organic revenue growth, driven by robust instrument placements and double-digit CAG diagnostics recurring revenue growth. Management initiated 2026 guidance for 7-9% organic revenue growth and 10-14% EPS growth, expecting continued macro headwinds but stable execution. Q4 2025 organic revenue growth of 12%, with CAG diagnostics recurring revenue up 10% organically.
IDEXX reported strong Q4 2025 results with 12% organic revenue growth, driven by robust instrument placements and double-digit CAG diagnostics recurring revenue growth. Management initiated 2026 guidance for 7-9% organic revenue growth and 10-14% EPS growth, expecting continued…
Q4 2025 organic revenue growth of 12%, with CAG diagnostics recurring revenue up 10% organically.
Record premium instrument placements in Q4, including over 1,900 InViewDX placements, supporting strong long-term consumable growth.
Guidance · revenue to $4.676B
Management highlighted several AI-powered innovations, including InViewDX for AI-powered cytology analysis and an AI-powered viewer in diagnostic imaging, which are contributing to product differentiation and customer adoption.
Management's guidance for 2026 is positive, expecting 7-9% organic revenue growth and 10-14% EPS growth, driven by continued innovation adoption and commercial execution despite macro headwinds.
The company increased its capital spending outlook for 2026 to $180 million, or approximately 4% of revenues, reflecting investments in capacity and infrastructure to support growth.
Management expressed confidence in their innovation-driven growth strategy and execution, despite acknowledging macro pressures on clinical visits.
“In the U.S., we anticipate net price improvement of approximately 3.5% and have incorporated declines in U.S. same-store clinical visit growth of approximately 2%, similar to the full year 2025, given ongoing macro and sector constraints.”
“guidance incorporates expectations for global net price realization of approximately 4%, reflecting a modestly lower net price realization than 2025.”
“keep in mind that the non-wellness visits, you know, represent about 60% of the visits, but 70% to 75% of the diagnostics revenue.”
“Now more than half of the lymphoma tests submitted are for screening versus as an aiding diagnosis.”
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| Capex | FY2026 | 180 | 180 | INITIATED |
| EPS | FY2026 | $14.29–$14.80 | $14.54 | INITIATED |
| Free cash flow | FY2026 | 85%–95% | 90% | INITIATED |
| Op margin | FY2026 | 32%–32.5% | 32.25% | INITIATED |
| Revenue | FY2026 | $4.632B–$4.72B | $4.676B | INITIATED |
IDEXX's guidance for 2026 embeds an assumption of continued ~2% decline in US same-store clinical visits (similar to 2025), citing macro and sector constraints. This suggests the broader veterinary sector is still experiencing weaker demand, which could impact other companies relying on the same end-market. — This signals a prolonged softness in the vet sector, impacting companies like Zoetis (ZTS) and Heska (acquired by Mars) that depend on the same veterinary clinic customer base.
… 2025 results. At current exchange rates, we expect foreign exchange to have an approximate 60 basis point benefit to full-year revenue growth, largely in the first half of the year. At midpoint, our 2026 organic CAG diagnostic recurring revenue growth outlook incorporates expectations for global net price realization of approximately 4%, reflecting a modestly lower net price realization than 2025. In the U.S., we anticipate net price improvement of approximately 3.5% and have incorporated declines in U.S. same-store clinical visit growth of approximately 2%, similar to the full year 2025, given ongoing macro and sector constraints. These targets incorporate continued solid global growth benefits from IDEX execution and innovation drivers, including new customer gains and increases in testing utilization. The higher end of our CAG diagnostic reoccurring revenue growth outlet captures the potential for improved sector and same-store growth trends, while the lower end of the range calibrates for further potential effects of macro and sector pressures. We're planning for solid placement levels for full year 2026 across our premium instrument install-based categories, including …
Despite soft clinical visits, IDEXX is seeing sustained growth in diagnostics frequency and utilization, particularly for non-wellness visits (60% of visits, 70-75% of diagnostics revenue). This signals a key trend in the sector: while visit counts are flat, the complexity and volume of testing per visit is increasing, leading to resilient diagnostics revenue growth.
Yeah, keep in mind that the non-wellness visits, you know, represent about 60% of the visits, but 70% to 75% of the diagnostics revenue. So this combination of what, you know, Andrew put his finger on, which is they're using more diagnostics when they come in. So we call that frequency. but also it's more intensive, I think is an important factor to keep in mind just through a diagnostic lens.